Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma.

ABSTRACT:

Background

Atezolizumab plus Bevacizumab is an effective treatment for unresectable hepatocellular carcinoma, but the assessment methods are limited.

Objective

To establish an early predictive model using Ultrasounic-radiomics (UR) for predicting the therapeutic efficacy of Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma.

Methods

We retrospectively analyzed 170 patients with unresectable hepatocellular carcinoma, extracting 1560 imaging features pre- and one-week post-treatment. Separate UR models were established to predict treatment efficacy. Model performance was evaluated using calibration curves and the area under the receiver operating characteristic curve (AUC).

Results

Two UR models were ultimately established. The pre-treatment U

SUBMITTER: Li Y 

PROVIDER: S-EPMC12571321 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature